-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. -
The Management of Atrial Fibrillation in Heart Failure: An Expert Panel ConsensusD Farmakis, C Chrysohoou, G Giamouzis et al.
-
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 InhibitorsS Verma, S Rawat, KL Ho et al.
-
Dilated cardiomyopathy: so many cardiomyopathies!G Sinagra, PM Elliott, M Merlo et al.
-
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHEREDewan P, Jackson A, Jhund PS et al.
-
Heart Failure and Atrial Fibrillation, Like Fire and FuryMA Carlisle, M Fudim, AD DeVore et al.
-
Primary Prevention of Heart Failure in WomenMA Daubert, PS Douglas.
-
Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failureHC Chang, CJ Huang, HM Cheng et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
